TSXV:ADK

Stock Analysis Report

Executive Summary

DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Share Price & News

How has DIAGNOS's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-13.8%

ADK

6.8%

CA Healthcare Services

0.1%

CA Market


1 Year Return

-75.0%

ADK

-25.9%

CA Healthcare Services

1.6%

CA Market

Return vs Industry: ADK underperformed the Canadian Healthcare Services industry which returned -25.9% over the past year.

Return vs Market: ADK underperformed the Canadian Market which returned 1.6% over the past year.


Shareholder returns

ADKIndustryMarket
7 Day-13.8%6.8%0.1%
30 Day-13.8%2.5%-2.9%
90 Day-58.3%25.6%-1.4%
1 Year-75.0%-75.0%-25.9%-25.9%5.2%1.6%
3 Year-72.2%-72.2%2.2%2.2%13.8%3.7%
5 Year-82.1%-82.1%49.7%48.6%25.3%7.2%

Price Volatility Vs. Market

How volatile is DIAGNOS's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is DIAGNOS undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether DIAGNOS is trading at an attractive price based on the cash flow it is expected to produce in the future. But as DIAGNOS has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of ADK’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through DIAGNOS regulatory filings.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is DIAGNOS forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as DIAGNOS has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has DIAGNOS performed over the past 5 years?

-10.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ADK is unprofitable, and losses have increased over the past 5 years at a rate of -10.2% per year.

Accelerating Growth: Unable to compare ADK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ADK is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-1.2%).


Return on Equity

High ROE: ADK's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: ADK is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: ADK is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is DIAGNOS's financial position?


Financial Position Analysis

Short Term Liabilities: ADK has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ADK has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ADK has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ADK's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: ADK has a low level of unsold assets or inventory.

Debt Coverage by Assets: ADK has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ADK has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ADK has less than a year of cash runway if free cash flow continues to reduce at historical rates of -6.3% each year


Next Steps

Dividend

What is DIAGNOS's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%6.0%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate ADK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ADK's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ADK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ADK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ADK's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of DIAGNOS's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average board tenure


CEO

André Larente 0

15.3yrs

Tenure

CA$272,279

Compensation

Mr. André Larente has been the Chief Executive Officer and President of Diagnos Inc. since June 22, 2004. Mr. Larente has been a Director at Albert Mining Inc. since May 31, 2017. Mr. Larente has been an E ...


CEO Compensation Analysis

Compensation vs. Market: André's total compensation ($USD207.34K) is about average for companies of similar size in the Canadian market ($USD121.84K).

Compensation vs Earnings: André's compensation has been consistent with company performance over the past year.


Board Age and Tenure

2.8yrs

Average Tenure

61yo

Average Age

Experienced Board: ADK's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyCA$17,50025 Dec 18
Maurice Pinsonnault Management Inc.
EntityCompany
Shares50,000
Max PriceCA$0.35
BuyCA$35,00021 Dec 18
Maurice Pinsonnault Management Inc.
EntityCompany
Shares100,000
Max PriceCA$0.35
BuyCA$750,00914 Nov 18
Maurice Pinsonnault Management Inc.
EntityCompany
Shares1,500,000
Max PriceCA$0.50
BuyCA$50,00004 Nov 18
Georges Hébert
EntityIndividual
Role
Member of the Board of Directors
Director
Shares100,000
Max PriceCA$0.50

Ownership Breakdown


Management Team

  • André Larente

    CEO, President & Executive Director

    • Tenure: 15.3yrs
    • Compensation: CA$272.28k
  • Marc-André Massue

    VP of Finance

    • Tenure: 11.4yrs
    • Compensation: CA$171.54k
  • Guillermo Robles

    Vice President of Sales

    • Tenure: 0yrs
    • Compensation: CA$159.75k
  • Hadi Chakor Djelthia

    Chief Medical Officer

    • Tenure: 0yrs

Board Members

  • François Côté (61yo)

    Chairman of the Board

    • Tenure: 0.08yrs
  • Georges Hébert (71yo)

    Director

    • Tenure: 2.8yrs
    • Compensation: CA$41.40k
  • André Larente

    CEO, President & Executive Director

    • Tenure: 15.3yrs
    • Compensation: CA$272.28k
  • David Wong

    Member of the Scientific Advisory Board

    • Tenure: 10.2yrs
  • David LeBrun

    Member of the Scientific Advisory Board

    • Tenure: 10.1yrs
  • Reid Maclellan (35yo)

    Director

    • Tenure: 1.5yrs
    • Compensation: CA$29.36k
  • Jean-Francois Yale

    Director

    • Tenure: 0.8yrs
    • Compensation: CA$8.81k

Company Information

DIAGNOS Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: DIAGNOS Inc.
  • Ticker: ADK
  • Exchange: TSXV
  • Founded: 1998
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: CA$5.337m
  • Shares outstanding: 42.69m
  • Website: https://www.diagnos.ca

Location

  • DIAGNOS Inc.
  • 7005 Taschereau Boulevard
  • Suite 340
  • Brossard
  • Quebec
  • J4Z 1A7
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ADKTSXV (TSX Venture Exchange)YesCommon SharesCACADNov 2000
4D4ADB (Deutsche Boerse AG)YesCommon SharesDEEURNov 2000
DGNO.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDNov 2000

Biography

DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. It offers image analysis services thro ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 23:34
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.